This brand name is authorized in Austria, Cyprus, Estonia, France, Ireland, Israel, Japan, Lithuania, Malta, Netherlands, Poland, South Africa, UK.
The drug MAALOX contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
LMI26O6933 - ALUMINUM OXIDE
|
|
Aluminium hydroxide is a slow-acting antacid. It is used to provide symptomatic relief in gastric hyperacidity. In addition, the antipeptic and demulcent activity of aluminium hydroxide helps to protect inflamed gastric mucosa against further irritation by gastric secretions. |
|
2
|
UNII
NBZ3QY004S - MAGNESIUM HYDROXIDE
|
|
Magnesium hydroxide is practically insoluble in water and solution is not effected until the hydroxide reacts with hydrochloric acid in the stomach to form magnesium chloride. Its neutralising action is almost equal to that of sodium bicarbonate. When the dose is in excess of that required to neutralise the acid the intragastric pH may reach pH 8 or 9. Acid rebound following magnesium hydroxide is clinically insignificant. Magnesium hydroxide has an indirect cathartic effect resulting from water retention in the intestinal lumen. |
|
Below package inserts are available for further reading:
| Document | Type | Information Source | |
|---|---|---|---|
| MAALOX Oral suspension | MPI, EU: SmPC | Health Products Regulatory Authority (IE) |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| A02AA04 | Magnesium hydroxide | A Alimentary tract and metabolism → A02 Drugs for acid related disorders → A02A Antacids → A02AA Magnesium compounds |
| A02AB01 | Aluminium hydroxide | A Alimentary tract and metabolism → A02 Drugs for acid related disorders → A02A Antacids → A02AB Aluminium compounds |
| A02AB10 | Combinations | A Alimentary tract and metabolism → A02 Drugs for acid related disorders → A02A Antacids → A02AB Aluminium compounds |
| A02AD01 | Ordinary salt combinations | A Alimentary tract and metabolism → A02 Drugs for acid related disorders → A02A Antacids → A02AD Combinations and complexes of aluminium, calcium and magnesium compounds |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| EE | Ravimiamet | 1009167, 1390531, 1390632, 1390643, 1645028, 1645039 |
| FR | Base de données publique des médicaments | 60330700, 62245483, 64216427, 67189387, 69221111, 69545939 |
| GB | Medicines & Healthcare Products Regulatory Agency | 347155 |
| IL | מִשְׂרַד הַבְּרִיאוּת | 1307 |
| JP | 医薬品医療機器総合機構 | 2349101D1253 |
| LT | Valstybinė vaistų kontrolės tarnyba | 1006908, 1006909, 1035290, 1035398, 1055196 |
| MT | Medicines Authority | AA1470/01401 |
| PL | Rejestru Produktów Leczniczych | 100082325, 100082331, 100291030 |
| ZA | Health Products Regulatory Authority | 42/11.4.1/0390, E/11.4.1/1271, E/11.4.1/1272 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.